JPH0134970B2 - - Google Patents
Info
- Publication number
- JPH0134970B2 JPH0134970B2 JP54131689A JP13168979A JPH0134970B2 JP H0134970 B2 JPH0134970 B2 JP H0134970B2 JP 54131689 A JP54131689 A JP 54131689A JP 13168979 A JP13168979 A JP 13168979A JP H0134970 B2 JPH0134970 B2 JP H0134970B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- homocysteine
- acid
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 60
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000003623 enhancer Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000002552 dosage form Substances 0.000 claims description 13
- 230000028993 immune response Effects 0.000 claims description 12
- KIWQWJKWBHZMDT-VKHMYHEASA-N L-homocysteine thiolactone Chemical compound N[C@H]1CCSC1=O KIWQWJKWBHZMDT-VKHMYHEASA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- FFFHZYDWPBMWHY-UHFFFAOYSA-N L-Homocysteine Natural products OC(=O)C(N)CCS FFFHZYDWPBMWHY-UHFFFAOYSA-N 0.000 claims description 4
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 4
- FFFHZYDWPBMWHY-GSVOUGTGSA-N D-Homocysteine Chemical compound OC(=O)[C@H](N)CCS FFFHZYDWPBMWHY-GSVOUGTGSA-N 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- KIWQWJKWBHZMDT-GSVOUGTGSA-N (3r)-3-aminothiolan-2-one Chemical compound N[C@@H]1CCSC1=O KIWQWJKWBHZMDT-GSVOUGTGSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- ZTVZLYBCZNMWCF-PHDIDXHHSA-N (2r)-2-azaniumyl-4-[[(3r)-3-azaniumyl-3-carboxylatopropyl]disulfanyl]butanoate Chemical compound OC(=O)[C@H](N)CCSSCC[C@@H](N)C(O)=O ZTVZLYBCZNMWCF-PHDIDXHHSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 150000003342 selenium Chemical class 0.000 claims 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 14
- DBZQFUNLCALWDY-PNHWDRBUSA-N (2r,3r,4s,5r)-2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=CC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O DBZQFUNLCALWDY-PNHWDRBUSA-N 0.000 description 12
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 12
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 12
- 229940095074 cyclic amp Drugs 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 9
- 229960005305 adenosine Drugs 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 5
- 102000055025 Adenosine deaminases Human genes 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- ZSEGSUBKDDEALH-UHFFFAOYSA-N 3-aminothiolan-2-one;hydron;chloride Chemical compound Cl.NC1CCSC1=O ZSEGSUBKDDEALH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002487 adenosine deaminase inhibitor Substances 0.000 description 3
- 150000003835 adenosine derivatives Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- ZTVZLYBCZNMWCF-UHFFFAOYSA-N homocystine Chemical compound [O-]C(=O)C([NH3+])CCSSCCC([NH3+])C([O-])=O ZTVZLYBCZNMWCF-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- IOSAAWHGJUZBOG-UHFFFAOYSA-N 3-(6-amino-9h-purin-9-yl)nonan-2-ol Chemical compound N1=CN=C2N(C(C(C)O)CCCCCC)C=NC2=C1N IOSAAWHGJUZBOG-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- 102100020925 Adenosylhomocysteinase Human genes 0.000 description 1
- 108020002202 Adenosylhomocysteinase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- KIWQWJKWBHZMDT-UHFFFAOYSA-N homocysteine thiolactone Chemical group NC1CCSC1=O KIWQWJKWBHZMDT-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000012177 negative regulation of immune response Effects 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical class O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
æ¬çºæã¯ã¢ããã·ã³èªå°äœãå«æããå»è¬çµæ
ç©ã«é¢ãããããã«è©³ããã¯ãæ¬çºæã¯ïŒâãã¢
ã¶ã¢ããã·ã³ãå«æããå»è¬çµæç©ã«é¢ããã ã¢ããã·ã³ãçœè¡çåªä»çŽ°è厩å£ïŒLMCïŒã®
匷åãªé»å®³å€ã§ããããšã¯å ¬ç¥ã§ããïŒScienceïŒ
N.Y.ïŒ187ïŒ957ïŒ1975ïŒïŒãã¢ããã·ã³ïŒã¢ããã·
ã³ãã¢ãããŒãŒïŒADAïŒã®äžååšã«ãã现èå
ã«ååšããïŒãå䜵åå ç«æ¬ æçã«é¢ä¿ããŠãã
ããšã瀺åãããŠãããããã¯ãã¢ããã·ã³ãã
ã®ä»ã®LMCé»å®³å€ããå ç«å¿çã®é»å®³ãæãŸã
ãå Žåã«ãå»è¬ãšããŠæçšã§ãããããšã瀺ããŠ
ããã ãã®åŸãæ°å€ãã®ã¢ããã·ã³èªå°äœãåãã匷
åãªLMCé»å®³å€ã§ããããšãå ±åãããŠãã
ïŒFederation ProceedingsïŒ35(3)ïŒ1213ïŒ1976ïŒïŒã
ãã®LMCé»å®³èœã¯ãã®çš®ã®èªå°äœã®çŽ°èå ãµã€
ã¯ãªãã¯AMPïŒCAMPïŒã¬ãã«ã«å¯Ÿããäœçšã«
é¢ä¿ããããšãæããã«ãããããã®èŠ³å¯ã¯åæ§
ã«ã¢ããã·ã³èªèº«ã«ãèªãããããããªãã¡ã
LMCã®åŒ·åãªé»å®³å€ã¯åæã«CAMPã®ã¬ãã«ã
ææã«å¢å ãããäžæŽ»æ§ãªååç©ã¯CAMPã¬ã
ã«ã«åœ±é¿ãäžããªãã€ããCAMPã¬ãã«ãäžæ
ãããªãã§LMCãé»å®³ããïŒïŒïŒã®ååç©ã¯ã
ã€ããããã®æŽ»æ§ã¬ãã«ã¯ããããŠäœãã
CAMPãäžæãããååç©ã¯LMCã®è¯å¥œãªé»å®³
å€ã§ããäžæ¹ãCAMPãäžæãããªãååç©ã¯
äžæŽ»æ§ã§ããããLMCã®åŒ±ãé»å®³å€ã§ããã«ã
ããªãã LMCãé»å®³ããã¢ããã·ã³ããã³å€ãã®ãã®
èªå°äœã®æ¬ ç¹ã¯ãã¢ããã·ã³ãã¢ãããŒãŒ
ïŒADAïŒã®åºè³ªã§ãã€ãŠããã®çç©æŽ»æ§ãå®å šã«
çºçŸããããã«ã¯ADAé»å®³å€ã®ååšãå¿ èŠãªç¹
ã§ããããã®çš®ã®é»å®³å€ãååšããªããšãæ¥éãª
äžæŽ»æ§åãèµ·ãããã掻æ§ã¯èããäœããªãã ã¢ããã·ã³ããã³LMCé»å®³å€ãšããŠå ¬ç¥ã®ã
ã®èªå°äœã®ä»ã®æ¬ ç¹ãšããŠã¯ãåºä¹³é¡åŸªç°ç³»ã«å¯Ÿ
ãããµã€ã¯ãªãã¯AMPã®å ¬ç¥äœçšããã¿ãŠãã
ã®äœçšæ©æ§ã¯æãŸãããªãå¯äœçšãå°ãããšãè
ããããç¹ãããã LMCãé»å®³ããæ°å€ãã®ã¢ããã·ã³èªå°äœã¯ã
掻æ§ãé«ããŠããæ¯æ§ã匷ãããããã€ãŠæ²»çä¿
æ°ã¯äœããªã€ãŠããŸããšããæ¬ ç¹ãããã ãŸããïŒâãã¢ã¶ã¢ããã·ã³ãâã¢ããã·ã«
ââãã¢ã·ã¹ãã€ã³ãããã©ãŒãŒã®åŒ·åãªé»å®³
å€ã§ããããã®æŽ»æ§ãã¢ããã·ã³ã®é¢é£é µçŽ ã«å¯Ÿ
ããåæ§ãªåŒ·ãäœçšã«é¢ä¿ããããšãå ±åãããŠ
ããïŒMol.PharmacolïŒ13ïŒ939â947ïŒ1977ïŒïŒã
ãã®åãå ±æã«ãïŒâãã¢ã¶ã¢ããã·ã³ãçç©åŠ
çåæäœãšããŠèšèŒãããŠããŠããã®ååç©ã¯çŽ°
èé·ç§»ããã³in vitroã§ã®Rous SarcomaãŠã€ã«
ã¹ã«ãããŠã€ã«ã¹ç£çãé»å®³ããããšãæ瀺ãã
ãŠããã æ¬çºæã¯ã以äžã®åŒïŒïŒã§å®çŸ©ãããïŒâã
ã¢ã¶ã¢ããã·ã³ããµã€ã¯ãªãã¯AMPã®ã¬ãã«ã«
ã¯ææãªåœ±é¿ãäžããªãã«ãããããããé©ãã¹
ãããšã«ãLMCã®åŒ·åãªé»å®³å€ã§ããããšãçº
èŠããå®æããããã®ã§ããããã®ååç©ã¯
ADAã®åºè³ªã§ã¯ãªãã æ¬çºæã®ååç©ã¯ãåŒïŒïŒ ïŒåŒäžR1ã¯ã¢ããã§ãããR2ã¯æ°ŽçŽ ã§ããã
R3ã¯æ°ŽçŽ ã§ããïŒã§ç€ºãããååç©ããã³ãã®
å»è¬çã«èš±å®¹ãããå¡©ã§ããã åŒïŒïŒã®ååç©ã¯ïŒâãã¢ã¶ã¢ããã·ã³ã§ã
ãã åŒïŒïŒã®ååç©ããã³ãã®å»è¬çã«èš±å®¹ãã
ãå¡©ã¯ãå ç«å¿çãæå¶ããããšãæãŸããå Žå
ã¯åžžã«æçšã§ãããåŒïŒïŒã®ååç©ã¯ããšã
ã°ããšãªããããŒãã¹ã溶è¡æ§è²§è¡ã朰çæ§å€§è ž
çããã³ããããŒãŒã®ãããªèªå·±å ç«çŸæ£ã®æ²»ç
ããã³èåšç§»æ€ãå«ãã移çžã®ãããªç°çš®çŽ°èã«
察ããæ絶ã®é²æ¢ã«æçšã§ããã ããªãã¡ãæ¬çºæã¯ãã®äžæ æ§ãšããŠãåŒ
ïŒïŒã®ååç©ãŸãã¯ãã®å»è¬çã«èš±å®¹ãããå¡©
ã®å»è¬ãšããŠã®äœ¿çšããšãã«å ç«å¿çã®æå¶ã«ã
ãã䜿çšãæäŸããã å»è¬çã«èš±å®¹ãããå¡©ãšããŠã¯é žä»å å¡©ãé©åœ
ã§ããã åŒïŒïŒã®ååç©ã®æŽ»æ§ã¯éé¢å¡©ã«ããã®ã§ã
ã€ãŠãé žä»å å¡©äžã®é žéšåã®æ§è³ªã¯ãšãã«éèŠã§
ã¯ãªããããããªãããå¡©ã¯éæ¯æ§é žããèªå°ã
ããããšã奜ãŸãããçšããããé žã¯éåžžãå»è¬
çã«èš±å®¹ãããé žä»å å¡©ãå°ããã®ã§ããã ãã®çš®ã®é žä»å å¡©ãšããŠã¯ãããšãã°ãå¡©é žã
ãšãŠåæ°ŽçŽ é žãç¡«é žãïœâãã«ãšã³ã¹ã«ãã³é žã
ã¡ã¿ã³ã¹ã«ãã³é žããã¬ã€ã³é žãä¹³é žãã¯ãšã³
é žãé ç³é žãã³ãã¯é žãã·ãŠãŠé žãïœâã¯ããã
ã³ãŒã³ã¹ã«ãã³é žããªã³é žãé ¢é žãã€ã»ããªã³
é žãã°ã«ã³ã³é žããã³ããã³é žããã³ã©ã¯ãããª
ã³é žããå°ãããå¡©ãæããããšãã§ããã åŒïŒïŒã®ååç©ã¯çŽç²ãªååç©ã®ãŸãŸæäžã
ãããšãã§ããããå»è¬çµæç©å€åãšããŠæäŸã
ãããšã奜ãŸããã ããªãã¡ãæ¬çºæã¯ããã«ã掻æ§ååç©ãå»è¬
çã«èš±å®¹ãããæ äœãšãšãã«å«æããå»è¬çµæç©
ãæäŸããããã®æ äœã¯ãçµæç©äžã®ä»ã®æåãš
é©åæ§ãæããã€è¢«æäžè ã«æ害ã§ãªããšããæ
å³ã§ã蚱容ãããããã®ã§ãªããã°ãªããªãã æ¬çºæã¯ããã«ã掻æ§ååç©ãšãã®å»è¬çã«èš±
容ãããæ äœãæ··åããããšã«ããå»è¬çµæç©ã®
補é æ¹æ³ããæäŸããã åŒïŒïŒã®ååç©ã¯åäœçšéå€åãšããŠæäŸã
ãã®ã䟿å©ã§ãããæå©ãªåäœçšéå€åã¯æŽ»æ§å
åç©ïŒmgãªããïŒïœã奜ãŸããã¯25mgãªãã500
mgããšãã«å¥œãŸããã¯100ãªãã300mgãå«æã
ãã å»è¬çµæç©ã¯çµå£ãçµçŽè žãŸãã¯éçµå£ïŒç泚
ããã³é泚ãå«ãïŒæäžã«é©ããå€åãšããããš
ãã§ããããšãã«çµå£æäžå€åãšããããšã奜ãŸ
ãããçµæç©ã¯ãããé©åœãªå Žåã«ã¯åé¢çšéå€
åãšããŠæäŸããä»»æã®å ¬ç¥è£œè¬æè¡ã«ãããã€
ãŠè£œé ã§ããã掻æ§ååç©ã液äœæ äœãããã¯åŸ®
ç²æ«åºäœæ äœãŸãã¯ãã®äž¡è ãšæ··åããã€ãã§å¿
èŠã«å¿ããŠææã®å€åã«æŽåããæ¹æ³ãæ¡çšã§ã
ãã æ äœãåºäœã§ããçµå£æäžçšå»è¬çµæç©ãåäœ
çšéå€åãšããŠã¯æãé©åœã§ãããšãã°ãããã
æ¢å®éã®æŽ»æ§ååç©ãå«æããäžžå€ãã«ãã»ã«ã
ãµãã·ãšãŸãã¯é å€ãšããããšãã§ãããé å€ã¯
ææã«ããïŒçš®ãŸãã¯ïŒçš®ä»¥äžã®è£å©æåãšãšã
ã«å§çž®ãŸãã¯æŽåããããšã«ãã€ãŠè£œé ã§ããã
å§çž®é å€ã¯åŒïŒïŒã®ååç©ãææã«ããçµå
å€ãæ»æ²¢å€ãäžæŽ»æ§åžéå€ãæ»æ²¢æ§è¡šé¢æŽ»æ§ãŸã
ã¯åæ£å€ãšæ··åããèªç±æµåæ§ç²æ«ãŸãã¯é¡ç²å€
åãšããé©åœãªæ©æ¢°ã§å§çž®ããŠè£œé ãããæŽåé
å€ã¯äžæŽ»æ§æ¶²äœåžéå€ãæŽåããããšã«ãã補é
ãããé å€ã¯ææã«ããã³ãŒãã€ã³ã°ãæœããŠã
ãããããŸãã³ãŒãã€ã³ã°ãæœããªãå Žåã«ã¯å²
ç·ãä»ãããšãã§ãããã«ãã»ã«ã¯åŒïŒïŒã®å
åç©ãåç¬ã§ããŸãã¯ïŒçš®ãŸãã¯ïŒçš®ä»¥äžã®è£å©
æåãšæ··åããŠã«ãã»ã«ã±ãŒã¹ã«å å¡«ããã€ãã§
ãããåžžæ³ã«ãã€ãŠã·ãŒã«ããããšãã補é ãã
ãããµãã·ãšã¯ã«ãã»ã«ãšåæ§ã掻æ§æåãè£å©
æåãšãšãã«ãªãã©ãŒãè¢ã«å°å ¥ããŠè£œé ãã
ãã æ äœã液äœã§ããçµå£æäžã«é©ããå»è¬çµæç©
ã¯ãæ°Žæ§æ¶²äœãããã¯éæ°Žæ§æ¶²äœäžãžã®æº¶æ¶²ãã
ãã¯æžæ¿æ¶²ããŸãã¯æ²¹äžæ°Žãããã¯æ°Žäžæ²¹ä¹³å液
ãšããŠäžããããã æ äœãåºäœã®çµçŽè žæäžã«é©ããå»è¬çµæç©ã¯
åäœçšéåå€ãæã奜ãŸãããé©åœãªæ äœãšããŠ
ã¯ã³ã³ã¢èããã³æ¬æè¡åéã§åžžçšãããä»ã®æ
æãæããããšãã§ãããåå€ã¯åŒïŒïŒã®åå
ç©ãè»åãŸãã¯çèæ äœãšæ··åããã€ãã§å·åŽ
ããåã®äžã§æŽåããããšã«ãã補é ã§ããã çµå£æäžã«é©ããå»è¬çµæç©ã«ã¯ãåŒïŒïŒã®
ååç©ã®æ°Žæ§ãŸãã¯æ²¹æ§ããŒã¯ã«äžæ» è溶液ãŸã
ã¯æžæ¿æ¶²ãããããã®çš®ã®è£œå€ã¯åäœçšéãŸãã¯
å€çšéçšå®¹åšã«å ¥ãã䜿çšãŸã§ã·ãŒã«ãã圢ã§æ
äŸãããã®ã䟿å©ã§ããã äžè¿°ã®æ äœæåã®ã»ãã«ãäžè¿°ã®å»è¬çµæç©ã«
ã¯ããã«é©å®ãïŒçš®ãŸãã¯ïŒçš®ä»¥äžã®æ äœæåã
ããšãã°åžéå€ãç·©è¡å€ããã¬ãŒããŒãçµåå€ã
çé¢æŽ»æ§å€ãå¢ç²å€ãæ»æ²¢å€ãé²è å€ïŒæé žåå€
ãå«ãïŒçããŸã被æäžè ã®è¡æ¶²ãšç匵ã«ããã
ãã®ç©è³ªãæ·»å ããããšãã§ããã ãã§ã«è¿°ã¹ãããã«ãæ¬çºæã®ååç©ã¯å ç«æ
å¶å€ãšããŠæçšã§ãããããªãã¡ãæ¬çºæã¯ãåŒ
ïŒïŒã®ååç©ãŸãã¯ãã®å»è¬çã«èš±å®¹ãããå¡©
ã®å ç«æå¶æå¹éãæäžããããããå«ããåºä¹³
é¡ã«ãããå ç«å¿çãæå¶ããæ¹æ³ããæäŸã
ãã æ²»çå¹æãåŸãã®ã«å¿ èŠãªåŒïŒïŒã®ååç©ã®
éã¯ããã¡ãããååç©ã®çš®é¡ã®ã¿ã§ãªãããã®
æäžçµè·¯ã«ãã€ãŠå€åãããäžè¬ã«åºä¹³é¡ïŒãã
ãå«ãïŒã®æ²»çã«é©åœãªçšéã¯ãå ç«å¿çã®é»å®³
ãå¿ èŠãªæéãïŒæ¥ã«ã€ããäœéïŒKgããã0.3
ãªãã100mgïŒmgïŒKgïŒã奜ãŸããã¯1.0ãªãã50
mgïŒKgããšãã«å¥œãŸããã¯ïŒãªãã15mgïŒKgã®ç¯
å²ã§ããã åŒïŒïŒã®ïŒâãã¢ã¶ã¢ããã·ã³ã¯æ¯æ§ã®äœã
ååç©ã§ãããå³ã¡ãã©ããã«çµå£æäžããŠåŸã
ããæ¥æ§æ¯æ§å€ïŒLD50ïŒã¯ãéæ§ã©ããã®å Žå
551mgïŒKgãéæ§ã©ããã®å Žå648mgïŒKgã§ããã
ãŸããããŠã¹ã«çµå£æäžããŠåŸãããLD50å€ã¯ã
éæ§ã©ããåã³éæ§ã©ãããšã5000mgïŒKg以äžã§
ããã ã¢ããã·ã³ã®ãªã³ãçã«å¯Ÿãã现èæ¯æ§äœçšã
âãã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³ã«ãã€ãŠåŒ·åã
ããããšã¯å ¬ç¥ã§ããïŒCellïŒ12ïŒ931â938
ïŒ1977ïŒïŒããã®é瀺ã¯ãã®çš®ã®æ¯æ§ãå䜵åå ç«
æ¬ æçã«é¢ä¿ããŠããããšã瀺åããŠããã æ¬çºæã¯ãŸããåŒïŒïŒã®ååç©ã®LMCé»å®³
äœçšãâãã¢ã·ã¹ãã€ã³ãâãã¢ã·ã¹ãã€
ã³ãâãã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³ãâãã¢
ã·ã¹ãã€ã³ããªã©ã¯ãã³ãâãã¢ã·ã¹ãã³ã
âãã¢ã·ã¹ãã³ããã³ãã®ã»ã¬ããŠã åæäœãã
ãªãååç©ïŒä»¥äžãå¹åå¢åŒ·å€ãšåŒã¶ïŒã®çŸ€ã«ã
ã€ãŠåŒ·åãããããšã®çºèŠã«ãé¢ä¿ããã âãã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³ã«ãããã®çš®
ã®å¹åå¢åŒ·ã¯ã¢ããã·ã³ã®LMCé»å®³äœçšã«å¯Ÿã
ãŠæåŸ ããããã®ã§ãããããã®äœçšæ©æ§ãå šã
å¥åãªããšãèããã°åŒïŒïŒã®ååç©ãå¢åŒ·ã
ãããšã¯é©ãã¹ãããšã§ããã ããªãã¡ãæ¬çºæã¯ããã«å¥ã®æ æ§ãšããŠãåŒ
ïŒïŒã®ååç©ãŸãã¯ãã®é žä»å å¡©ãšãäžã«å®çŸ©
ããå¹åå¢åŒ·å€ãšãããªãå»è¬çµæç©ãæäŸã
ãã 奜ãŸããçµåãã¯ïŒâãã¢ã¶ã¢ããã·ã³ãšïŒ¬â
ãã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³ã§ããã ãã®çµåãã¯å ç«å¿çã®æå¶ã«æçšã§ãããã
ãªãã¡ãåŒïŒïŒã®ååç©ã䜿çšã§ããäžè¿°ã®ç¶
æ ã®æ²»çã«äœ¿çšã§ããã åŒïŒïŒã®ååç©ãšå¹åå¢åŒ·å€ã¯ã€ã¥ããŠæäž
ããŠãããããåæã«æäžããŠãããããããã®
ååç©ã¯çŽç²ãªååç©ã®ãŸãŸæäžããŠããããã
åäžã®ãŸãã¯å¥åã®å»è¬çµæç©ãšããŠæäžããã
ãšã奜ãŸããã åŒïŒïŒã®ååç©ãšå¹åå¢åŒ·å€ãå¥åã®çµæç©
ãšããŠæäžããå ŽåãåŒïŒïŒã®ååç©ã¯åè¿°ã®
ãããªçµæç©ãšããŠæäžããã®ãé©åœã§ããã å¹åå¢åŒ·å€ãå¥åã®çµæç©ãšããŠæäžããå Ž
åãçµæç©ã¯åŒïŒïŒã®ååç©ã«ã€ããŠåè¿°ãã
ãšåäžã®çµæç©ãšããã®ãé©åœã§ãããåè¿°ãã
ãšåæ§ã«ããŠè£œé ã§ãããå¥åã«æäžããå Žåã
å¹åå¢åŒ·å€ã¯åäœçšéå€åãšããã®ã䟿å©ã§ã
ããæå©ãªåäœçšéå€åã¯10mgãªããïŒïœã®å¹å
å¢åŒ·å€ãå«æããã åŒïŒïŒã®ååç©ãšå¹åå¢åŒ·å€ã¯å¥åã«æäžã
ãŠãããããäž¡è ã¯ïŒåã®å€åã«ããŠæäžããã®
ãæå©ã§ããã ããªãã¡ãæ¬çºæã¯ããã«ãåŒïŒïŒã®ååç©
ïŒå ã«å®çŸ©ãããšããã§ããïŒãŸãã¯ãã®å»è¬ç
ã«èš±å®¹ãããå¡©ããã³å¹åå¢åŒ·å€ïŒå ã«å®çŸ©ãã
ãšããã§ããïŒãšãã®å»è¬çã«èš±å®¹ãããæ äœãš
ãããªãå»è¬çµæç©ãæäŸããã蚱容ãããã®èª
ã¯å ã«å®çŸ©ãããšåãæå³ã§çšãããããã®ã§ã
ãã æ¬çºæã¯ããã«ãåŒïŒïŒã®ååç©ãšå¹åå¢åŒ·
å€ãå»è¬çã«èš±å®¹ãããæ äœãšæ··åããå»è¬çµæ
ç©ã®è£œé æ¹æ³ããå å«ããã ãã®çµæç©ã¯ãåŒïŒïŒã®ååç©ãšå¹åå¢åŒ·å€
ã¯æ¯çïŒïŒ100ãªããïŒïŒ10ã奜ãŸããã¯ïŒïŒ50
ãªããïŒïŒ20ããšãã«å¥œãŸããã¯ïŒïŒ30ã§å«æã
ãã®ãé©åœã§ãããåäœçšéå€åãšããã®ã䟿å©
ã§ãããæå©ãªåäœçšéå€åã¯åŒïŒïŒã®ååç©
ïŒmgãªãã100mgãšãšãã«ãäžè¿°ã®æ¯ã«çžåœãã
å¹åå¢åŒ·å€50mgãªããïŒïœãå«æããã ãã®çµæç©ã«ã¯çµå£ãçµçŽè žããã³éçµå£ïŒç
泚ããã³é泚ãå«ãïŒæäžã«é©ããå€åãå å«ã
ããããçµå£ã奜ãŸããæäžçµè·¯ã§ããããã®çš®
ã®çµæç©ã¯åŒïŒïŒã®ååç©åç¬ã®å Žåã«ã€ããŠ
åè¿°ãããšåããã®ãé©åœã§ããããŸãåæ§ã«è£œ
é ã§ããã ãããã€ãŠãæ¬çºæã¯åŒïŒïŒã®ååç©ïŒå ã«
å®çŸ©ãããšããã§ããïŒãŸãã¯ãã®å»è¬çã«èš±å®¹
ãããå¡©ããå¹åå¢åŒ·å€ïŒå ã«å®çŸ©ãããšããã§
ããïŒã®å¢åŒ·æå¹éãšãšãã«æäžããããããå«
ããåºä¹³é¡ã«ãããå ç«å¿çã®é»å®³æ¹æ³ãæäŸã
ãã å¢åŒ·æå¹éãšã¯ãåŒïŒïŒã®ååç©ãå ç«å¿ç
ã®é»å®³ã«äžååãªéæäžããå ŽåãåŒïŒïŒã®å
åç©ã®å¹æãå ç«å¿çã®é»å®³ãéæãããã¬ãã«
ãŸã§å¢åŒ·ããå¹åå¢éå€ã®éãæå³ããã å¿ èŠãªåŒïŒïŒã®ååç©ã®éã¯ããã¡ããåå
ç©ã®çš®é¡ããã³æäžçµè·¯ã«ãã€ãŠå€åããããå
æã«å¹åå¢åŒ·å€ã®çš®é¡ããã³ãã®æäžéã«ãã€ãŠ
ãå€åãããåŒïŒïŒã®ååç©ã¯ãåç¬ã§ã¯å ç«
å¿çãæå¹ã«é»å®³ããªãçšéã§æäžããã®ã奜ãŸ
ãããåŒïŒïŒã®ååç©ãšå¹åå¢åŒ·å€ã®æäžéã®
æ¯ã¯ïŒïŒ100ãªããïŒïŒ10ã奜ãŸããã¯ïŒïŒ50ãª
ããïŒïŒ20ããšãã«å¥œãŸããã¯ïŒïŒ30ã§ãããã
ããå«ããåºä¹³é¡ã®å ç«å¿çã®é»å®³ã«é©åœãªçšé
ã¯äžè¬ã«ãå ç«å¿çã®é»å®³ãå¿ èŠãªæéäžãïŒ
æ¥ãäœéïŒKgãããåŒïŒïŒã®ååç©0.3mgãªã
ã100mgãäœéïŒKgãããå¹åå¢åŒ·å€ïŒmgãªãã
ïŒïœã奜ãŸããã¯ïŒmgãªãã100mgã§ããã 次ã«æ¬çºæã以äžã®å®æœäŸã«ããããã«è©³çŽ°ã«
説æããããããã¯æ¬çºæãåã«äŸç€ºãããã®ã§
ãã€ãŠãæ¬çºæãéå®ãããã®ã§ã¯ãªãã äŸ ïŒ in vitroã«ããããªã³ãçåªä»çŽ°è厩å£
ïŒLMCïŒã®æ€å® è©Šéšååç©ã¯ScienceïŒN.Y.187ïŒ957ïŒ1975ïŒ
ã«èšèŒãããæ¹æ³ã«ããin vitroã§æ€å®ãããè©Š
è¬ã®æ·»å é åºã¯(1)现èæ¯æ§ãªã³ãçã(2)ãã€ããž
ãšã³ãå«ãŸãªãé£å¡©æ°Žã«æº¶è§£ããè©Šéšååç©ã(3)
51Crã©ãã«EL4现èã§ãããADAé»å®³å€ãå¿ èŠ
ãªå®éšã®å Žåã¯ãEHNA+ãå·¥çš(2)ã®åã«ãæçµ
æ¿åºŠ7.0ÎŒMãšãªãããã«æ·»å ãããæ€å®ã¯ïŒ¬âã
ã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³ïŒ200ÎŒMïŒãå ããŠ
ãŸãã¯å ããªãã§å®æœãããçµæãè¡šïŒã«ç€ºãã
ç©ã«é¢ãããããã«è©³ããã¯ãæ¬çºæã¯ïŒâãã¢
ã¶ã¢ããã·ã³ãå«æããå»è¬çµæç©ã«é¢ããã ã¢ããã·ã³ãçœè¡çåªä»çŽ°è厩å£ïŒLMCïŒã®
匷åãªé»å®³å€ã§ããããšã¯å ¬ç¥ã§ããïŒScienceïŒ
N.Y.ïŒ187ïŒ957ïŒ1975ïŒïŒãã¢ããã·ã³ïŒã¢ããã·
ã³ãã¢ãããŒãŒïŒADAïŒã®äžååšã«ãã现èå
ã«ååšããïŒãå䜵åå ç«æ¬ æçã«é¢ä¿ããŠãã
ããšã瀺åãããŠãããããã¯ãã¢ããã·ã³ãã
ã®ä»ã®LMCé»å®³å€ããå ç«å¿çã®é»å®³ãæãŸã
ãå Žåã«ãå»è¬ãšããŠæçšã§ãããããšã瀺ããŠ
ããã ãã®åŸãæ°å€ãã®ã¢ããã·ã³èªå°äœãåãã匷
åãªLMCé»å®³å€ã§ããããšãå ±åãããŠãã
ïŒFederation ProceedingsïŒ35(3)ïŒ1213ïŒ1976ïŒïŒã
ãã®LMCé»å®³èœã¯ãã®çš®ã®èªå°äœã®çŽ°èå ãµã€
ã¯ãªãã¯AMPïŒCAMPïŒã¬ãã«ã«å¯Ÿããäœçšã«
é¢ä¿ããããšãæããã«ãããããã®èŠ³å¯ã¯åæ§
ã«ã¢ããã·ã³èªèº«ã«ãèªãããããããªãã¡ã
LMCã®åŒ·åãªé»å®³å€ã¯åæã«CAMPã®ã¬ãã«ã
ææã«å¢å ãããäžæŽ»æ§ãªååç©ã¯CAMPã¬ã
ã«ã«åœ±é¿ãäžããªãã€ããCAMPã¬ãã«ãäžæ
ãããªãã§LMCãé»å®³ããïŒïŒïŒã®ååç©ã¯ã
ã€ããããã®æŽ»æ§ã¬ãã«ã¯ããããŠäœãã
CAMPãäžæãããååç©ã¯LMCã®è¯å¥œãªé»å®³
å€ã§ããäžæ¹ãCAMPãäžæãããªãååç©ã¯
äžæŽ»æ§ã§ããããLMCã®åŒ±ãé»å®³å€ã§ããã«ã
ããªãã LMCãé»å®³ããã¢ããã·ã³ããã³å€ãã®ãã®
èªå°äœã®æ¬ ç¹ã¯ãã¢ããã·ã³ãã¢ãããŒãŒ
ïŒADAïŒã®åºè³ªã§ãã€ãŠããã®çç©æŽ»æ§ãå®å šã«
çºçŸããããã«ã¯ADAé»å®³å€ã®ååšãå¿ èŠãªç¹
ã§ããããã®çš®ã®é»å®³å€ãååšããªããšãæ¥éãª
äžæŽ»æ§åãèµ·ãããã掻æ§ã¯èããäœããªãã ã¢ããã·ã³ããã³LMCé»å®³å€ãšããŠå ¬ç¥ã®ã
ã®èªå°äœã®ä»ã®æ¬ ç¹ãšããŠã¯ãåºä¹³é¡åŸªç°ç³»ã«å¯Ÿ
ãããµã€ã¯ãªãã¯AMPã®å ¬ç¥äœçšããã¿ãŠãã
ã®äœçšæ©æ§ã¯æãŸãããªãå¯äœçšãå°ãããšãè
ããããç¹ãããã LMCãé»å®³ããæ°å€ãã®ã¢ããã·ã³èªå°äœã¯ã
掻æ§ãé«ããŠããæ¯æ§ã匷ãããããã€ãŠæ²»çä¿
æ°ã¯äœããªã€ãŠããŸããšããæ¬ ç¹ãããã ãŸããïŒâãã¢ã¶ã¢ããã·ã³ãâã¢ããã·ã«
ââãã¢ã·ã¹ãã€ã³ãããã©ãŒãŒã®åŒ·åãªé»å®³
å€ã§ããããã®æŽ»æ§ãã¢ããã·ã³ã®é¢é£é µçŽ ã«å¯Ÿ
ããåæ§ãªåŒ·ãäœçšã«é¢ä¿ããããšãå ±åãããŠ
ããïŒMol.PharmacolïŒ13ïŒ939â947ïŒ1977ïŒïŒã
ãã®åãå ±æã«ãïŒâãã¢ã¶ã¢ããã·ã³ãçç©åŠ
çåæäœãšããŠèšèŒãããŠããŠããã®ååç©ã¯çŽ°
èé·ç§»ããã³in vitroã§ã®Rous SarcomaãŠã€ã«
ã¹ã«ãããŠã€ã«ã¹ç£çãé»å®³ããããšãæ瀺ãã
ãŠããã æ¬çºæã¯ã以äžã®åŒïŒïŒã§å®çŸ©ãããïŒâã
ã¢ã¶ã¢ããã·ã³ããµã€ã¯ãªãã¯AMPã®ã¬ãã«ã«
ã¯ææãªåœ±é¿ãäžããªãã«ãããããããé©ãã¹
ãããšã«ãLMCã®åŒ·åãªé»å®³å€ã§ããããšãçº
èŠããå®æããããã®ã§ããããã®ååç©ã¯
ADAã®åºè³ªã§ã¯ãªãã æ¬çºæã®ååç©ã¯ãåŒïŒïŒ ïŒåŒäžR1ã¯ã¢ããã§ãããR2ã¯æ°ŽçŽ ã§ããã
R3ã¯æ°ŽçŽ ã§ããïŒã§ç€ºãããååç©ããã³ãã®
å»è¬çã«èš±å®¹ãããå¡©ã§ããã åŒïŒïŒã®ååç©ã¯ïŒâãã¢ã¶ã¢ããã·ã³ã§ã
ãã åŒïŒïŒã®ååç©ããã³ãã®å»è¬çã«èš±å®¹ãã
ãå¡©ã¯ãå ç«å¿çãæå¶ããããšãæãŸããå Žå
ã¯åžžã«æçšã§ãããåŒïŒïŒã®ååç©ã¯ããšã
ã°ããšãªããããŒãã¹ã溶è¡æ§è²§è¡ã朰çæ§å€§è ž
çããã³ããããŒãŒã®ãããªèªå·±å ç«çŸæ£ã®æ²»ç
ããã³èåšç§»æ€ãå«ãã移çžã®ãããªç°çš®çŽ°èã«
察ããæ絶ã®é²æ¢ã«æçšã§ããã ããªãã¡ãæ¬çºæã¯ãã®äžæ æ§ãšããŠãåŒ
ïŒïŒã®ååç©ãŸãã¯ãã®å»è¬çã«èš±å®¹ãããå¡©
ã®å»è¬ãšããŠã®äœ¿çšããšãã«å ç«å¿çã®æå¶ã«ã
ãã䜿çšãæäŸããã å»è¬çã«èš±å®¹ãããå¡©ãšããŠã¯é žä»å å¡©ãé©åœ
ã§ããã åŒïŒïŒã®ååç©ã®æŽ»æ§ã¯éé¢å¡©ã«ããã®ã§ã
ã€ãŠãé žä»å å¡©äžã®é žéšåã®æ§è³ªã¯ãšãã«éèŠã§
ã¯ãªããããããªãããå¡©ã¯éæ¯æ§é žããèªå°ã
ããããšã奜ãŸãããçšããããé žã¯éåžžãå»è¬
çã«èš±å®¹ãããé žä»å å¡©ãå°ããã®ã§ããã ãã®çš®ã®é žä»å å¡©ãšããŠã¯ãããšãã°ãå¡©é žã
ãšãŠåæ°ŽçŽ é žãç¡«é žãïœâãã«ãšã³ã¹ã«ãã³é žã
ã¡ã¿ã³ã¹ã«ãã³é žããã¬ã€ã³é žãä¹³é žãã¯ãšã³
é žãé ç³é žãã³ãã¯é žãã·ãŠãŠé žãïœâã¯ããã
ã³ãŒã³ã¹ã«ãã³é žããªã³é žãé ¢é žãã€ã»ããªã³
é žãã°ã«ã³ã³é žããã³ããã³é žããã³ã©ã¯ãããª
ã³é žããå°ãããå¡©ãæããããšãã§ããã åŒïŒïŒã®ååç©ã¯çŽç²ãªååç©ã®ãŸãŸæäžã
ãããšãã§ããããå»è¬çµæç©å€åãšããŠæäŸã
ãããšã奜ãŸããã ããªãã¡ãæ¬çºæã¯ããã«ã掻æ§ååç©ãå»è¬
çã«èš±å®¹ãããæ äœãšãšãã«å«æããå»è¬çµæç©
ãæäŸããããã®æ äœã¯ãçµæç©äžã®ä»ã®æåãš
é©åæ§ãæããã€è¢«æäžè ã«æ害ã§ãªããšããæ
å³ã§ã蚱容ãããããã®ã§ãªããã°ãªããªãã æ¬çºæã¯ããã«ã掻æ§ååç©ãšãã®å»è¬çã«èš±
容ãããæ äœãæ··åããããšã«ããå»è¬çµæç©ã®
補é æ¹æ³ããæäŸããã åŒïŒïŒã®ååç©ã¯åäœçšéå€åãšããŠæäŸã
ãã®ã䟿å©ã§ãããæå©ãªåäœçšéå€åã¯æŽ»æ§å
åç©ïŒmgãªããïŒïœã奜ãŸããã¯25mgãªãã500
mgããšãã«å¥œãŸããã¯100ãªãã300mgãå«æã
ãã å»è¬çµæç©ã¯çµå£ãçµçŽè žãŸãã¯éçµå£ïŒç泚
ããã³é泚ãå«ãïŒæäžã«é©ããå€åãšããããš
ãã§ããããšãã«çµå£æäžå€åãšããããšã奜ãŸ
ãããçµæç©ã¯ãããé©åœãªå Žåã«ã¯åé¢çšéå€
åãšããŠæäŸããä»»æã®å ¬ç¥è£œè¬æè¡ã«ãããã€
ãŠè£œé ã§ããã掻æ§ååç©ã液äœæ äœãããã¯åŸ®
ç²æ«åºäœæ äœãŸãã¯ãã®äž¡è ãšæ··åããã€ãã§å¿
èŠã«å¿ããŠææã®å€åã«æŽåããæ¹æ³ãæ¡çšã§ã
ãã æ äœãåºäœã§ããçµå£æäžçšå»è¬çµæç©ãåäœ
çšéå€åãšããŠã¯æãé©åœã§ãããšãã°ãããã
æ¢å®éã®æŽ»æ§ååç©ãå«æããäžžå€ãã«ãã»ã«ã
ãµãã·ãšãŸãã¯é å€ãšããããšãã§ãããé å€ã¯
ææã«ããïŒçš®ãŸãã¯ïŒçš®ä»¥äžã®è£å©æåãšãšã
ã«å§çž®ãŸãã¯æŽåããããšã«ãã€ãŠè£œé ã§ããã
å§çž®é å€ã¯åŒïŒïŒã®ååç©ãææã«ããçµå
å€ãæ»æ²¢å€ãäžæŽ»æ§åžéå€ãæ»æ²¢æ§è¡šé¢æŽ»æ§ãŸã
ã¯åæ£å€ãšæ··åããèªç±æµåæ§ç²æ«ãŸãã¯é¡ç²å€
åãšããé©åœãªæ©æ¢°ã§å§çž®ããŠè£œé ãããæŽåé
å€ã¯äžæŽ»æ§æ¶²äœåžéå€ãæŽåããããšã«ãã補é
ãããé å€ã¯ææã«ããã³ãŒãã€ã³ã°ãæœããŠã
ãããããŸãã³ãŒãã€ã³ã°ãæœããªãå Žåã«ã¯å²
ç·ãä»ãããšãã§ãããã«ãã»ã«ã¯åŒïŒïŒã®å
åç©ãåç¬ã§ããŸãã¯ïŒçš®ãŸãã¯ïŒçš®ä»¥äžã®è£å©
æåãšæ··åããŠã«ãã»ã«ã±ãŒã¹ã«å å¡«ããã€ãã§
ãããåžžæ³ã«ãã€ãŠã·ãŒã«ããããšãã補é ãã
ãããµãã·ãšã¯ã«ãã»ã«ãšåæ§ã掻æ§æåãè£å©
æåãšãšãã«ãªãã©ãŒãè¢ã«å°å ¥ããŠè£œé ãã
ãã æ äœã液äœã§ããçµå£æäžã«é©ããå»è¬çµæç©
ã¯ãæ°Žæ§æ¶²äœãããã¯éæ°Žæ§æ¶²äœäžãžã®æº¶æ¶²ãã
ãã¯æžæ¿æ¶²ããŸãã¯æ²¹äžæ°Žãããã¯æ°Žäžæ²¹ä¹³å液
ãšããŠäžããããã æ äœãåºäœã®çµçŽè žæäžã«é©ããå»è¬çµæç©ã¯
åäœçšéåå€ãæã奜ãŸãããé©åœãªæ äœãšããŠ
ã¯ã³ã³ã¢èããã³æ¬æè¡åéã§åžžçšãããä»ã®æ
æãæããããšãã§ãããåå€ã¯åŒïŒïŒã®åå
ç©ãè»åãŸãã¯çèæ äœãšæ··åããã€ãã§å·åŽ
ããåã®äžã§æŽåããããšã«ãã補é ã§ããã çµå£æäžã«é©ããå»è¬çµæç©ã«ã¯ãåŒïŒïŒã®
ååç©ã®æ°Žæ§ãŸãã¯æ²¹æ§ããŒã¯ã«äžæ» è溶液ãŸã
ã¯æžæ¿æ¶²ãããããã®çš®ã®è£œå€ã¯åäœçšéãŸãã¯
å€çšéçšå®¹åšã«å ¥ãã䜿çšãŸã§ã·ãŒã«ãã圢ã§æ
äŸãããã®ã䟿å©ã§ããã äžè¿°ã®æ äœæåã®ã»ãã«ãäžè¿°ã®å»è¬çµæç©ã«
ã¯ããã«é©å®ãïŒçš®ãŸãã¯ïŒçš®ä»¥äžã®æ äœæåã
ããšãã°åžéå€ãç·©è¡å€ããã¬ãŒããŒãçµåå€ã
çé¢æŽ»æ§å€ãå¢ç²å€ãæ»æ²¢å€ãé²è å€ïŒæé žåå€
ãå«ãïŒçããŸã被æäžè ã®è¡æ¶²ãšç匵ã«ããã
ãã®ç©è³ªãæ·»å ããããšãã§ããã ãã§ã«è¿°ã¹ãããã«ãæ¬çºæã®ååç©ã¯å ç«æ
å¶å€ãšããŠæçšã§ãããããªãã¡ãæ¬çºæã¯ãåŒ
ïŒïŒã®ååç©ãŸãã¯ãã®å»è¬çã«èš±å®¹ãããå¡©
ã®å ç«æå¶æå¹éãæäžããããããå«ããåºä¹³
é¡ã«ãããå ç«å¿çãæå¶ããæ¹æ³ããæäŸã
ãã æ²»çå¹æãåŸãã®ã«å¿ èŠãªåŒïŒïŒã®ååç©ã®
éã¯ããã¡ãããååç©ã®çš®é¡ã®ã¿ã§ãªãããã®
æäžçµè·¯ã«ãã€ãŠå€åãããäžè¬ã«åºä¹³é¡ïŒãã
ãå«ãïŒã®æ²»çã«é©åœãªçšéã¯ãå ç«å¿çã®é»å®³
ãå¿ èŠãªæéãïŒæ¥ã«ã€ããäœéïŒKgããã0.3
ãªãã100mgïŒmgïŒKgïŒã奜ãŸããã¯1.0ãªãã50
mgïŒKgããšãã«å¥œãŸããã¯ïŒãªãã15mgïŒKgã®ç¯
å²ã§ããã åŒïŒïŒã®ïŒâãã¢ã¶ã¢ããã·ã³ã¯æ¯æ§ã®äœã
ååç©ã§ãããå³ã¡ãã©ããã«çµå£æäžããŠåŸã
ããæ¥æ§æ¯æ§å€ïŒLD50ïŒã¯ãéæ§ã©ããã®å Žå
551mgïŒKgãéæ§ã©ããã®å Žå648mgïŒKgã§ããã
ãŸããããŠã¹ã«çµå£æäžããŠåŸãããLD50å€ã¯ã
éæ§ã©ããåã³éæ§ã©ãããšã5000mgïŒKg以äžã§
ããã ã¢ããã·ã³ã®ãªã³ãçã«å¯Ÿãã现èæ¯æ§äœçšã
âãã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³ã«ãã€ãŠåŒ·åã
ããããšã¯å ¬ç¥ã§ããïŒCellïŒ12ïŒ931â938
ïŒ1977ïŒïŒããã®é瀺ã¯ãã®çš®ã®æ¯æ§ãå䜵åå ç«
æ¬ æçã«é¢ä¿ããŠããããšã瀺åããŠããã æ¬çºæã¯ãŸããåŒïŒïŒã®ååç©ã®LMCé»å®³
äœçšãâãã¢ã·ã¹ãã€ã³ãâãã¢ã·ã¹ãã€
ã³ãâãã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³ãâãã¢
ã·ã¹ãã€ã³ããªã©ã¯ãã³ãâãã¢ã·ã¹ãã³ã
âãã¢ã·ã¹ãã³ããã³ãã®ã»ã¬ããŠã åæäœãã
ãªãååç©ïŒä»¥äžãå¹åå¢åŒ·å€ãšåŒã¶ïŒã®çŸ€ã«ã
ã€ãŠåŒ·åãããããšã®çºèŠã«ãé¢ä¿ããã âãã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³ã«ãããã®çš®
ã®å¹åå¢åŒ·ã¯ã¢ããã·ã³ã®LMCé»å®³äœçšã«å¯Ÿã
ãŠæåŸ ããããã®ã§ãããããã®äœçšæ©æ§ãå šã
å¥åãªããšãèããã°åŒïŒïŒã®ååç©ãå¢åŒ·ã
ãããšã¯é©ãã¹ãããšã§ããã ããªãã¡ãæ¬çºæã¯ããã«å¥ã®æ æ§ãšããŠãåŒ
ïŒïŒã®ååç©ãŸãã¯ãã®é žä»å å¡©ãšãäžã«å®çŸ©
ããå¹åå¢åŒ·å€ãšãããªãå»è¬çµæç©ãæäŸã
ãã 奜ãŸããçµåãã¯ïŒâãã¢ã¶ã¢ããã·ã³ãšïŒ¬â
ãã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³ã§ããã ãã®çµåãã¯å ç«å¿çã®æå¶ã«æçšã§ãããã
ãªãã¡ãåŒïŒïŒã®ååç©ã䜿çšã§ããäžè¿°ã®ç¶
æ ã®æ²»çã«äœ¿çšã§ããã åŒïŒïŒã®ååç©ãšå¹åå¢åŒ·å€ã¯ã€ã¥ããŠæäž
ããŠãããããåæã«æäžããŠãããããããã®
ååç©ã¯çŽç²ãªååç©ã®ãŸãŸæäžããŠããããã
åäžã®ãŸãã¯å¥åã®å»è¬çµæç©ãšããŠæäžããã
ãšã奜ãŸããã åŒïŒïŒã®ååç©ãšå¹åå¢åŒ·å€ãå¥åã®çµæç©
ãšããŠæäžããå ŽåãåŒïŒïŒã®ååç©ã¯åè¿°ã®
ãããªçµæç©ãšããŠæäžããã®ãé©åœã§ããã å¹åå¢åŒ·å€ãå¥åã®çµæç©ãšããŠæäžããå Ž
åãçµæç©ã¯åŒïŒïŒã®ååç©ã«ã€ããŠåè¿°ãã
ãšåäžã®çµæç©ãšããã®ãé©åœã§ãããåè¿°ãã
ãšåæ§ã«ããŠè£œé ã§ãããå¥åã«æäžããå Žåã
å¹åå¢åŒ·å€ã¯åäœçšéå€åãšããã®ã䟿å©ã§ã
ããæå©ãªåäœçšéå€åã¯10mgãªããïŒïœã®å¹å
å¢åŒ·å€ãå«æããã åŒïŒïŒã®ååç©ãšå¹åå¢åŒ·å€ã¯å¥åã«æäžã
ãŠãããããäž¡è ã¯ïŒåã®å€åã«ããŠæäžããã®
ãæå©ã§ããã ããªãã¡ãæ¬çºæã¯ããã«ãåŒïŒïŒã®ååç©
ïŒå ã«å®çŸ©ãããšããã§ããïŒãŸãã¯ãã®å»è¬ç
ã«èš±å®¹ãããå¡©ããã³å¹åå¢åŒ·å€ïŒå ã«å®çŸ©ãã
ãšããã§ããïŒãšãã®å»è¬çã«èš±å®¹ãããæ äœãš
ãããªãå»è¬çµæç©ãæäŸããã蚱容ãããã®èª
ã¯å ã«å®çŸ©ãããšåãæå³ã§çšãããããã®ã§ã
ãã æ¬çºæã¯ããã«ãåŒïŒïŒã®ååç©ãšå¹åå¢åŒ·
å€ãå»è¬çã«èš±å®¹ãããæ äœãšæ··åããå»è¬çµæ
ç©ã®è£œé æ¹æ³ããå å«ããã ãã®çµæç©ã¯ãåŒïŒïŒã®ååç©ãšå¹åå¢åŒ·å€
ã¯æ¯çïŒïŒ100ãªããïŒïŒ10ã奜ãŸããã¯ïŒïŒ50
ãªããïŒïŒ20ããšãã«å¥œãŸããã¯ïŒïŒ30ã§å«æã
ãã®ãé©åœã§ãããåäœçšéå€åãšããã®ã䟿å©
ã§ãããæå©ãªåäœçšéå€åã¯åŒïŒïŒã®ååç©
ïŒmgãªãã100mgãšãšãã«ãäžè¿°ã®æ¯ã«çžåœãã
å¹åå¢åŒ·å€50mgãªããïŒïœãå«æããã ãã®çµæç©ã«ã¯çµå£ãçµçŽè žããã³éçµå£ïŒç
泚ããã³é泚ãå«ãïŒæäžã«é©ããå€åãå å«ã
ããããçµå£ã奜ãŸããæäžçµè·¯ã§ããããã®çš®
ã®çµæç©ã¯åŒïŒïŒã®ååç©åç¬ã®å Žåã«ã€ããŠ
åè¿°ãããšåããã®ãé©åœã§ããããŸãåæ§ã«è£œ
é ã§ããã ãããã€ãŠãæ¬çºæã¯åŒïŒïŒã®ååç©ïŒå ã«
å®çŸ©ãããšããã§ããïŒãŸãã¯ãã®å»è¬çã«èš±å®¹
ãããå¡©ããå¹åå¢åŒ·å€ïŒå ã«å®çŸ©ãããšããã§
ããïŒã®å¢åŒ·æå¹éãšãšãã«æäžããããããå«
ããåºä¹³é¡ã«ãããå ç«å¿çã®é»å®³æ¹æ³ãæäŸã
ãã å¢åŒ·æå¹éãšã¯ãåŒïŒïŒã®ååç©ãå ç«å¿ç
ã®é»å®³ã«äžååãªéæäžããå ŽåãåŒïŒïŒã®å
åç©ã®å¹æãå ç«å¿çã®é»å®³ãéæãããã¬ãã«
ãŸã§å¢åŒ·ããå¹åå¢éå€ã®éãæå³ããã å¿ èŠãªåŒïŒïŒã®ååç©ã®éã¯ããã¡ããåå
ç©ã®çš®é¡ããã³æäžçµè·¯ã«ãã€ãŠå€åããããå
æã«å¹åå¢åŒ·å€ã®çš®é¡ããã³ãã®æäžéã«ãã€ãŠ
ãå€åãããåŒïŒïŒã®ååç©ã¯ãåç¬ã§ã¯å ç«
å¿çãæå¹ã«é»å®³ããªãçšéã§æäžããã®ã奜ãŸ
ãããåŒïŒïŒã®ååç©ãšå¹åå¢åŒ·å€ã®æäžéã®
æ¯ã¯ïŒïŒ100ãªããïŒïŒ10ã奜ãŸããã¯ïŒïŒ50ãª
ããïŒïŒ20ããšãã«å¥œãŸããã¯ïŒïŒ30ã§ãããã
ããå«ããåºä¹³é¡ã®å ç«å¿çã®é»å®³ã«é©åœãªçšé
ã¯äžè¬ã«ãå ç«å¿çã®é»å®³ãå¿ èŠãªæéäžãïŒ
æ¥ãäœéïŒKgãããåŒïŒïŒã®ååç©0.3mgãªã
ã100mgãäœéïŒKgãããå¹åå¢åŒ·å€ïŒmgãªãã
ïŒïœã奜ãŸããã¯ïŒmgãªãã100mgã§ããã 次ã«æ¬çºæã以äžã®å®æœäŸã«ããããã«è©³çŽ°ã«
説æããããããã¯æ¬çºæãåã«äŸç€ºãããã®ã§
ãã€ãŠãæ¬çºæãéå®ãããã®ã§ã¯ãªãã äŸ ïŒ in vitroã«ããããªã³ãçåªä»çŽ°è厩å£
ïŒLMCïŒã®æ€å® è©Šéšååç©ã¯ScienceïŒN.Y.187ïŒ957ïŒ1975ïŒ
ã«èšèŒãããæ¹æ³ã«ããin vitroã§æ€å®ãããè©Š
è¬ã®æ·»å é åºã¯(1)现èæ¯æ§ãªã³ãçã(2)ãã€ããž
ãšã³ãå«ãŸãªãé£å¡©æ°Žã«æº¶è§£ããè©Šéšååç©ã(3)
51Crã©ãã«EL4现èã§ãããADAé»å®³å€ãå¿ èŠ
ãªå®éšã®å Žåã¯ãEHNA+ãå·¥çš(2)ã®åã«ãæçµ
æ¿åºŠ7.0ÎŒMãšãªãããã«æ·»å ãããæ€å®ã¯ïŒ¬âã
ã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³ïŒ200ÎŒMïŒãå ããŠ
ãŸãã¯å ããªãã§å®æœãããçµæãè¡šïŒã«ç€ºãã
ãè¡šã
ãè¡šã
ããã³
ïŒ ADAé»å®³å€ã®ååšäžã«è©Šéš
äŸ ïŒ è©Šéšååç©ã®ãµã€ã¯ãªãã¯AMPã¬ãã«ã«å¯Ÿã
ãåœ±é¿ ãªã³ãçã®é žå¯æº¶æ§æœåºæ¶²äžã«ååšãããµã€ã¯
ãªãã¯AMPã®ã¬ãã«ãããªã³ãçãšè©Šéšååç©
ã30åéã€ã³ããŠããŒã·ãšã³ããã®ã¡æž¬å®ããã
ãµã€ã¯ãªãã¯AMPã®ã¬ãã«ã¯ãé žåã¢ã«ãããŠ
ã ããã³Dowex1âX8æš¹èé£ç¶ã«ã©ã äžã§æœåº
液ã粟補ããã€ãã§åŸããããµã³ãã«ã2â²âïŒâ
ã¹ã¯ã·ãã«åããã®ã¡ãå ¬ç¥ã®æŸå°å ç«å®éæ³ã§
枬å®ãããåŸãããçµæãè¡šïŒã«ç€ºãã
ïŒ ADAé»å®³å€ã®ååšäžã«è©Šéš
äŸ ïŒ è©Šéšååç©ã®ãµã€ã¯ãªãã¯AMPã¬ãã«ã«å¯Ÿã
ãåœ±é¿ ãªã³ãçã®é žå¯æº¶æ§æœåºæ¶²äžã«ååšãããµã€ã¯
ãªãã¯AMPã®ã¬ãã«ãããªã³ãçãšè©Šéšååç©
ã30åéã€ã³ããŠããŒã·ãšã³ããã®ã¡æž¬å®ããã
ãµã€ã¯ãªãã¯AMPã®ã¬ãã«ã¯ãé žåã¢ã«ãããŠ
ã ããã³Dowex1âX8æš¹èé£ç¶ã«ã©ã äžã§æœåº
液ã粟補ããã€ãã§åŸããããµã³ãã«ã2â²âïŒâ
ã¹ã¯ã·ãã«åããã®ã¡ãå ¬ç¥ã®æŸå°å ç«å®éæ³ã§
枬å®ãããåŸãããçµæãè¡šïŒã«ç€ºãã
ãè¡šã
äŸ ïŒ
以äžã®æåããé å€ã補é ããã
ïŒé äžå«é
ïŒâãã¢ã¶ã¢ããã·ã³ 200mg
ä¹³ ç³ 170mg
銬éŽè¯ãã³ãã³ïŒä¹Ÿç¥ïŒ 28.6mg
ã¹ãã¢ãªã³é
žãã°ãã·ãŠã 1.4mg
èš400.0mg
äŸ ïŒ
以äžã®æåããé å€ã補é ããã
ïŒé äžå«é
ïŒâãã¢ã¶ã¢ããã·ã³ 10mg
âãã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³å¡©é
žå¡© 390mg
ä¹³ ç³ 160mg
銬éŽè¯ãã³ãã³ïŒä¹Ÿç¥ïŒ 38mg
ã¹ãã¢ãªã³é
žãã°ãã·ãŠã ïŒmg
èš600.0mg
äŸ ïŒ
以äžã®æåããåå€ã補é ããã
ïŒåå€äžå«é
ïŒâãã¢ã¶ã¢ããã·ã³ 20mg
âãã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³å¡©é
žå¡© 780mg
ã«ã«ãªè 2000mg
äŸ ïŒ
以äžã®æåããã·ãããå€ã補é ããã
10mläžå«é
ïŒâãã¢ã¶ã¢ããã·ã³ 10mg
âãã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³å¡©é
žå¡© 390mg
ã°ãªã»ãªã³ ïŒïœ
庶 ç³ ïŒïœ
ã¡ãã«ãã©ãã³ 10mg
å®æ¯éŠé
žãããªãŠã 10mg
ããšãªãŒãã¬ãŒã㌠0.1ml
çè²æ é© é
粟補氎 å
šé10.0mlãšãã
äŸ ïŒ
以äžã®æåãã泚å°å€ã補é ããã
ïŒã¢ã³ãã«äžå«é
ïŒâãã¢ã¶ã¢ããã·ã³ 10mg
âãã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³ 390mg
å¡©åãããªãŠã 8.5mg
泚å°çšæ°Ž å
šé1.0mlãšããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ åŒ ïŒåŒäžR1ã¯ã¢ããã§ãããR2ã¯æ°ŽçŽ ã§ããã
R3ã¯æ°ŽçŽ ã§ããïŒã§ç€ºãããååç©ãŸãã¯ãã®
å»è¬çã«èš±å®¹ãããå¡©ãå»è¬çã«èš±å®¹ãããæ äœ
ãšãšãã«å«æããå ç«å¿çæå¶çšå»è¬çµæç©ã ïŒ åäœçšéå€åãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èš
èŒã®å»è¬çµæç©ã ïŒ åŒ ïŒåŒäžR1ã¯ã¢ããã§ãããR2ã¯æ°ŽçŽ ã§ããã
R3ã¯æ°ŽçŽ ã§ããïŒã§ç€ºãããååç©ãŸãã¯ãã®
å¡©ãåã³ãâãã¢ã·ã¹ãã€ã³ãâãã¢ã·ã¹ã
ã€ã³ãâãã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³ãâã
ã¢ã·ã¹ãã€ã³ããªã©ã¯ãã³ãâãã¢ã·ã¹ãã³ã
âãã¢ã·ã¹ãã³ããã³ãã®ã»ã¬ããŠã åæäœã
ãéžã°ããå¹åå¢åŒ·å€ããå»è¬çã«èš±å®¹ãããæ
äœãšãšãã«å«æããå ç«å¿çæå¶çšå»è¬çµæç©ã ïŒ å¹åå¢åŒ·å€ãšããŠïŒ¬âãã¢ã·ã¹ãã€ã³ããªã©
ã¯ãã³ãå«æããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®å»
è¬çµæç©ã ïŒ åŒïŒïŒã®ååç©ãšå¹åå¢åŒ·å€ãšãééæ¯
ïŒïŒ100ããïŒïŒ10ã®å²åã§å«æããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé ãŸãã¯ç¬¬ïŒé èšèŒã®å»è¬çµæç©ã
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB7840447 | 1978-10-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5555199A JPS5555199A (en) | 1980-04-22 |
JPH0134970B2 true JPH0134970B2 (ja) | 1989-07-21 |
Family
ID=10500310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP13168979A Granted JPS5555199A (en) | 1978-10-13 | 1979-10-12 | Adenosine derivative |
Country Status (6)
Country | Link |
---|---|
US (1) | US4309419A (ja) |
EP (1) | EP0010668B1 (ja) |
JP (1) | JPS5555199A (ja) |
DE (1) | DE2967570D1 (ja) |
DK (1) | DK431879A (ja) |
IT (1) | IT1164735B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2074858B (en) * | 1980-04-23 | 1985-03-20 | Wellcome Found | Compositions containing 3-deazaaden-osine |
IT1170909B (it) * | 1980-04-23 | 1987-06-03 | Wellcome Found | Composizione per il trattamento di infiammazioni a base di analoghi della adenosina e procedimento di preparazione relativo |
US4481197A (en) * | 1980-04-25 | 1984-11-06 | Burroughs Wellcome Co. | Anti-inflammatory deoxyribosides |
US4322411A (en) * | 1980-04-25 | 1982-03-30 | Burroughs Wellcome Co. | Anti-inflammatory nucleosides |
US4388308A (en) * | 1980-06-09 | 1983-06-14 | G.D. Searle & Co. | N6 -[(2-Hydroxypropyl)aryl]adenosines |
US4680285A (en) * | 1980-12-15 | 1987-07-14 | Viratek, Inc. | Treatment of malignant tumors with 2-(β-D-ribofuranosylthiazole-4-carboxamide related compounds |
US4386093A (en) * | 1981-09-16 | 1983-05-31 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | (±)3-Deazaaristeromycin and uses |
US4780452A (en) * | 1986-09-08 | 1988-10-25 | Burroughs Wellcome Co. | F-substituted-3-β-D-ribofuranosyl-3H-imidazo[4,5-b]pyridines and pharmaceutical compositions thereof |
US4931431A (en) * | 1986-09-15 | 1990-06-05 | Livingston William S | Arthritis treatment with hypoxanthine |
US4853373A (en) * | 1986-09-15 | 1989-08-01 | Livingston William S | Therapeutic treatment for arthritic condition |
US4918060A (en) * | 1987-09-04 | 1990-04-17 | The Johns Hopkins University | Method of treating myasthenia gravis and related diseases |
US4880784A (en) * | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
US5308837A (en) * | 1990-08-22 | 1994-05-03 | Merrell Dow Pharmaceuticals Inc. | 5'-amine substituted adenosine analogs as immunosuppressants |
US5137876A (en) * | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
US5747474A (en) * | 1996-07-29 | 1998-05-05 | Immune Modulation, Inc. | Immunosuppression by administration of N6,N6 -disubstituted cAMP's, analogues thereof, and related nucleosides |
US6693088B1 (en) | 1998-09-03 | 2004-02-17 | Kerckhoff-Klinik Gesellschaft MIT BeschrÀnkter Haftung | 3-deazaadenosine prevents atherosclerosis and graft vasculopathy |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3919193A (en) * | 1973-07-06 | 1975-11-11 | Icn Pharmaceuticals | 3-Deazaguanosine and derivatives thereof |
US4148888A (en) * | 1978-03-13 | 1979-04-10 | The United States Of America As Represented By The Department Of Health, Education And Welfare | 3-Deazaadenosine as an inhibitor of adenosylhomocysteine hydrolase with antiviral activity |
-
1979
- 1979-10-12 DE DE7979103947T patent/DE2967570D1/de not_active Expired
- 1979-10-12 JP JP13168979A patent/JPS5555199A/ja active Granted
- 1979-10-12 EP EP79103947A patent/EP0010668B1/en not_active Expired
- 1979-10-12 IT IT50555/79A patent/IT1164735B/it active
- 1979-10-12 US US06/084,445 patent/US4309419A/en not_active Expired - Lifetime
- 1979-10-12 DK DK431879A patent/DK431879A/da not_active Application Discontinuation
Non-Patent Citations (2)
Title |
---|
CHEM PHARM BULL=1968 * |
JOURNAL OF MEDINAL CHEMISTRY=1974 * |
Also Published As
Publication number | Publication date |
---|---|
DE2967570D1 (en) | 1986-03-06 |
JPS5555199A (en) | 1980-04-22 |
DK431879A (da) | 1980-04-14 |
EP0010668A1 (en) | 1980-05-14 |
IT1164735B (it) | 1987-04-15 |
EP0010668B1 (en) | 1986-01-22 |
US4309419A (en) | 1982-01-05 |
IT7950555A0 (it) | 1979-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0134970B2 (ja) | ||
US20040204481A1 (en) | Activation of natural killer cells by adenosine A3 receptor agonists | |
US4322411A (en) | Anti-inflammatory nucleosides | |
HU201672B (en) | Process for producing pharmaceutical compositions comprising podophyllotoxin | |
AU628113B2 (en) | 2',3'-dideoxypurine nucleoside/purine nucleoside phosphorylase inhibitor combination therapy and composition | |
AP1141A (en) | A pharmaceutical composition comprising lamivudine or its derivatives that can be effectively preserved by parabens. | |
SK50696A3 (en) | Flavin and its derivatives as anti-viral agents | |
US4362741A (en) | Therapeutic composition for preventing the aggregation of platelets | |
EP0038567B1 (en) | Deazapurine nucleoside, formulations thereof, and use thereof in therapy | |
JP3276762B2 (ja) | ã€ãœãããªã³èªå°äœãå«æããå»è¬çµæç© | |
US5102883A (en) | Pyrimidine biosynthesis inhibitors useful as immunosuppressive agents | |
CA2262765A1 (en) | Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv | |
JPS6245525A (ja) | è質äœäžå€ | |
EP0728002B1 (en) | Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 infection | |
CA2167841A1 (en) | Method of inhibiting the production of human immunodeficiency viruses with substituted azaspiranes | |
WO1992016200A1 (en) | The use of hydroxamic acid derivatives to inhibit viral replication | |
JPH09500646A (ja) | ã¢ã¶ã¹ãã©ã³ã«ããïœïœïœã®æ²»çæ³ | |
EP0624089A1 (en) | Methods | |
US3502774A (en) | Anthelmintic method using 6-methoxy-1-phenazinol 5,10-dioxide | |
JPH09500648A (ja) | 眮æã¢ã¶ã¹ãã©ã³ã«ããããå ç«äžå šãŠã€ã«ã¹è€è£œã®é»å®³æ³ | |
JPS63107926A (ja) | è¡äžè質æ¹åå€ | |
US3749780A (en) | Method of treating malaria with 3-(p-chlorophenyl)-6-lower alkylamino or dilower alkylamino-s-tetrazines | |
JPH05339156A (ja) | ããè «ç现èã«å¯Ÿããéžæç现èéå®³å€ | |
JPH07196489A (ja) | ããè «ç现èã«å¯Ÿããéžæç现èéå®³å€ | |
JPH02174721A (ja) | è質äœäžå€ |